New Drugs 2020 – Nurse Practitioner

  Price  $10.00

  Credits  2

Clear


Format
During 2020, the global pandemic pressured the FDA to focus on treatments, diagnostic tests, and prevention measures for SARS-CoV-2, the cause of COVID-19. However, the agency still approved 53 drugs as new molecular entities or new biologics – an increase over the 48 novel drugs approved in 2019. This issue summarizes key information on new, first-in-class medications for cholesterol management and two common skin conditions (acne vulgaris and actinic keratosis); the first drug for peanut allergy; the first oral gonadotropin-releasing hormone antagonist for prostate cancer; a new and improved pediculicide and ovicide for head lice; and a new catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease. A brief summary of 4 new oral therapies for non-small cell lung cancer (NSCLC) is also included. Usual dosing recommendations and drug interactions are provided in Table 1.Brief descriptions of 14 additional new drugs that may be commonly prescribed are provided in Table 2.
$10.00

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Nurse Practitioner

Author
James Chan
PharmD, PhD
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • For drugs reviewed in detail, provide the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and its potential role in therapy.
  • For drugs reviewed in detail, describe significant warnings and precautions. Provide 2-3 patient counseling tips for each.
  • For the briefly summarized drugs in Table 2, state the generic/brand names, dosage form(s), FDA approved indication(s), and safety concerns, if discussed. 
  • Briefly describe the new, targeted therapies for the treatment of NSCLC (eg, how they work, role in therapy).

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    20-876774
  • Universal Activity Number:
    Nurse Practitioner : 0798-0000-21-185-H01
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.